ABSTRACT
Purpose Relapse is a major cause of failure in human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC). Clinicopathologic criteria for adjuvant treatment remain imprecise and have not changed for decades. We investigated whether circulating tumor DNA (ctDNA) in lymphatic exudate collected via surgical drains (“lymph”) 24-hours after surgery identified molecular residual disease (MRD) and compared its performance to time-matched plasma.
Experimental Design Using an ultra-sensitive tumor-informed sequencing approach, tumor variants were called in lymph and plasma to classify patients as ctDNA-positive or ctDNA-negative, trained in an initial cohort of 36 patients and replicated in an independent cohort of 37 patients. Progression-free survival (PFS) was compared in ctDNA+ vs. ctDNA-patients.
Results Lymph identified MRD in two independent multi-site cohorts (initial cohort sensitivity = 75%, specificity = 60%, P = 0.03; replication cohort sensitivity = 67%, specificity = 68%, P = 0.05). Lymph performance was enhanced in locoregional relapse (sensitivity = 80%, specificity = 64%, P = 0.001) and generalized to early-stage patients. Analysis of matched plasma collected at this early timepoint was not predictive of recurrence (sensitivity = 33%, specificity = 70%, P = 0.82). In patients with intermediate-risk pathology, lymph ctDNA was associated with recurrence (sensitivity = 88%, specificity = 64%, P = 0.002), suggesting an opportunity for improved stratification of patients who may benefit from additional adjuvant treatment.
Conclusion We demonstrate a liquid biopsy approach using a historically overlooked biofluid to potentially enhance precision adjuvant therapy and achieve superior oncologic outcomes.
Translational Relevance Postoperative lymphatic exudate represents a proximal analyte for MRD detection in HPV-HNSCC designed specifically for use in the immediate post-surgical window when adjuvant therapy decisions must be made. Accurate MRD identification at this early timepoint has the potential to augment traditional pathology and personalize adjuvant treatment paradigms in HPV-negative HNSCC.
Competing Interest Statement
A.A.C. is employed at Mayo Clinic as Associate Professor. A.A.C. serves on the advisory board at the following organizations: Illumina Advisory Board, Research Support; Roche: Advisory Board, Research Support; AstraZeneca: Advisory Board; Caris: Advisory Board. A.A.C. reports the following interests: Droplet Biosciences (ownership); LiquidCell Dx (ownership); CytoTrace Biosciences (ownership); Geneoscopy (stock options). J.P.Z. reports the following interests: Droplet Biosciences, Founder, equity shareholder; share IP Vine Medical, Equity share holder; Chair of Scientific Advisory Board, share IP; Merck, Consultant and Mark Investigator Studies Program (MISP) recipient. S.S.L., Z.G., A.H., M.L., A.T., A.B. and W.W. are employees of Droplet Biosciences. M.S.F. and M.P. are consultants to Droplet Biosciences. S.S.L., Z.G., A.H., M.L., A.T., A.B., M.S.F. and W.W. report the following interests: Droplet Biosciences (shareholders). A.E.G., E.L.V., A.G., M.S., S.H.R., and T.J.J. are employees of Labcorp and hold equity in Labcorp.
Funding Statement
This study was funded by Droplet Biosciences, Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Washington University School of Medicine gave ethical approval for this work. Ethics committee/IRB of University of Pittsburgh Medical Center gave ethical approval for this work. Institutional Review Board approval from Discovery Life Sciences (Alabama, USA)] gave ethical approval for collection of commercially procured reference population of noncancerous donor plasma samples.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Author affiliations updated. Method section updated to provide additional details on processing and quality control. Result section updated to add orthogonal validation and further results. Figure 1, 3, SFig 1 revised. SFig 2-5 added. Supplemental files updated.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
